You are here
P&T December 2012
FDA approvals, drug indications, and updates
Mirabegron (Myrbetriq) for overactive bladder; phentermine/topiramate ER (Qsymia) for weight management; and ocriplasmin injection (Jetrea) for vitreomacular adhesion
Topics include comparisons of bivalirudin (Angiomax) and unfractionated heparin in reducing bleeding, prasugrel (Effient) and clopidogrel (Plavix) in acute myocardial infarction, aspirin for critical limb ischemia, and mobilized CD34+ cells for angina.